These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
347 related articles for article (PubMed ID: 37365198)
1. PET-validated EEG-machine learning algorithm predicts brain amyloid pathology in pre-dementia Alzheimer's disease. Kim NH; Park U; Yang DW; Choi SH; Youn YC; Kang SW Sci Rep; 2023 Jun; 13(1):10299. PubMed ID: 37365198 [TBL] [Abstract][Full Text] [Related]
2. Machine Learning to Predict Brain Amyloid Pathology in Pre-dementia Alzheimer's Disease Using QEEG Features and Genetic Algorithm Heuristic. Kim NH; Yang DW; Choi SH; Kang SW Front Comput Neurosci; 2021; 15():755499. PubMed ID: 34867252 [TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of Amyloid Binding in Cognitively Impaired Patients Consecutively Recruited from a Memory Clinic: Evaluating the Utility of Quantitative 18F-Flutemetamol PET-CT in Discrimination of Mild Cognitive Impairment from Alzheimer's Disease and Other Dementias. Bao YW; Chau ACM; Chiu PK; Shea YF; Kwan JSK; Chan FHW; Mak HK J Alzheimers Dis; 2021; 79(2):819-832. PubMed ID: 33361593 [TBL] [Abstract][Full Text] [Related]
4. The Precuneus - A Witness for Excessive Aβ Gathering in Alzheimer's Disease Pathology. Aghakhanyan G; Vergallo A; Gennaro M; Mazzarri S; Guidoccio F; Radicchi C; Ceravolo R; Tognoni G; Bonuccelli U; Volterrani D Neurodegener Dis; 2018; 18(5-6):302-309. PubMed ID: 30814473 [TBL] [Abstract][Full Text] [Related]
5. Diagnosed mild cognitive impairment due to Alzheimer's disease with PET biomarkers of beta amyloid and neuronal dysfunction. Hatashita S; Yamasaki H PLoS One; 2013; 8(6):e66877. PubMed ID: 23799136 [TBL] [Abstract][Full Text] [Related]
6. A Head-to-Head Comparison Between Plasma pTau181 and Tau PET Along the Alzheimer's Disease Continuum. Coomans EM; Verberk IMW; Ossenkoppele R; Verfaillie SCJ; Visser D; Gouda M; Tuncel H; Wolters EE; Timmers T; Windhorst AD; Golla SSV; Scheltens P; van WM; Flier D; van Berckel BNM; Teunissen CE J Nucl Med; 2023 Mar; 64(3):437-443. PubMed ID: 36229187 [TBL] [Abstract][Full Text] [Related]
7. Quantitative Radiomic Features as New Biomarkers for Alzheimer's Disease: An Amyloid PET Study. Ding Y; Zhao K; Che T; Du K; Sun H; Liu S; Zheng Y; Li S; Liu B; Liu Y; Cereb Cortex; 2021 Jul; 31(8):3950-3961. PubMed ID: 33884402 [TBL] [Abstract][Full Text] [Related]
8. Predicting progression from subjective cognitive decline to mild cognitive impairment or dementia based on brain atrophy patterns. Lerch O; Ferreira D; Stomrud E; van Westen D; Tideman P; Palmqvist S; Mattsson-Carlgren N; Hort J; Hansson O; Westman E Alzheimers Res Ther; 2024 Jul; 16(1):153. PubMed ID: 38970077 [TBL] [Abstract][Full Text] [Related]
9. Discriminative Power of Arterial Spin Labeling Magnetic Resonance Imaging and 18F-Fluorodeoxyglucose Positron Emission Tomography Changes for Amyloid-β-Positive Subjects in the Alzheimer's Disease Continuum. Tosun D; Schuff N; Jagust W; Weiner MW; Neurodegener Dis; 2016; 16(1-2):87-94. PubMed ID: 26560336 [TBL] [Abstract][Full Text] [Related]
10. Improved Risk Stratification for Progression from Mild Cognitive Impairment to Alzheimer's Disease with a Multi-Analytical Evaluation of Amyloid-β Positron Emission Tomography. Beyer L; Brendel M; Scheiwein F; Sauerbeck J; Hosakawa C; Alberts I; Shi K; Bartenstein P; Ishii K; Seibyl J; Cumming P; Rominger A; J Alzheimers Dis; 2020; 74(1):101-112. PubMed ID: 31985461 [TBL] [Abstract][Full Text] [Related]
11. Predictive Accuracy of Blood-Derived Biomarkers for Amyloid-β Brain Deposition Along with the Alzheimer's Disease Continuum: A Systematic Review. Cianflone A; Coppola L; Mirabelli P; Salvatore M J Alzheimers Dis; 2021; 84(1):393-407. PubMed ID: 34542072 [TBL] [Abstract][Full Text] [Related]
12. Amyloid-β misfolding as a plasma biomarker indicates risk for future clinical Alzheimer's disease in individuals with subjective cognitive decline. Stockmann J; Verberk IMW; Timmesfeld N; Denz R; Budde B; Lange-Leifhelm J; Scheltens P; van der Flier WM; Nabers A; Teunissen CE; Gerwert K Alzheimers Res Ther; 2020 Dec; 12(1):169. PubMed ID: 33357241 [TBL] [Abstract][Full Text] [Related]
14. Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer's Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness. Teipel SJ; Kuper-Smith JO; Bartels C; Brosseron F; Buchmann M; Buerger K; Catak C; Janowitz D; Dechent P; Dobisch L; Ertl-Wagner B; Fließbach K; Haynes JD; Heneka MT; Kilimann I; Laske C; Li S; Menne F; Metzger CD; Priller J; Pross V; Ramirez A; Scheffler K; Schneider A; Spottke A; Spruth EJ; Wagner M; Wiltfang J; Wolfsgruber S; Düzel E; Jessen F; Dyrba M; J Alzheimers Dis; 2019; 72(2):455-465. PubMed ID: 31594223 [TBL] [Abstract][Full Text] [Related]
15. Association of short-term cognitive decline and MCI-to-AD dementia conversion with CSF, MRI, amyloid- and Ottoy J; Niemantsverdriet E; Verhaeghe J; De Roeck E; Struyfs H; Somers C; Wyffels L; Ceyssens S; Van Mossevelde S; Van den Bossche T; Van Broeckhoven C; Ribbens A; Bjerke M; Stroobants S; Engelborghs S; Staelens S Neuroimage Clin; 2019; 22():101771. PubMed ID: 30927601 [TBL] [Abstract][Full Text] [Related]
16. Biomarker-Based Prediction of Longitudinal Tau Positron Emission Tomography in Alzheimer Disease. Leuzy A; Smith R; Cullen NC; Strandberg O; Vogel JW; Binette AP; Borroni E; Janelidze S; Ohlsson T; Jögi J; Ossenkoppele R; Palmqvist S; Mattsson-Carlgren N; Klein G; Stomrud E; Hansson O JAMA Neurol; 2022 Feb; 79(2):149-158. PubMed ID: 34928318 [TBL] [Abstract][Full Text] [Related]
17. Early detection of amyloid load using Bullich S; Roé-Vellvé N; Marquié M; Landau SM; Barthel H; Villemagne VL; Sanabria Á; Tartari JP; Sotolongo-Grau O; Doré V; Koglin N; Müller A; Perrotin A; Jovalekic A; De Santi S; Tárraga L; Stephens AW; Rowe CC; Sabri O; Seibyl JP; Boada M Alzheimers Res Ther; 2021 Mar; 13(1):67. PubMed ID: 33773598 [TBL] [Abstract][Full Text] [Related]
18. In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging. Zhao Y; Raichle ME; Wen J; Benzinger TL; Fagan AM; Hassenstab J; Vlassenko AG; Luo J; Cairns NJ; Christensen JJ; Morris JC; Yablonskiy DA Neuroimage; 2017 Mar; 148():296-304. PubMed ID: 27989773 [TBL] [Abstract][Full Text] [Related]
19. Alzheimer's cerebrospinal biomarkers from Lumipulse fully automated immunoassay: concordance with amyloid-beta PET and manual immunoassay in Koreans : CSF AD biomarkers measured by Lumipulse in Koreans. Moon S; Kim S; Mankhong S; Choi SH; Vandijck M; Kostanjevecki V; Jeong JH; Yoon SJ; Park KW; Kim EJ; Yoon B; Kim HJ; Jang JW; Hong JY; Park DH; Shaw LM; Kang JH Alzheimers Res Ther; 2021 Jan; 13(1):22. PubMed ID: 33436035 [TBL] [Abstract][Full Text] [Related]
20. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model. Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W; J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]